Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exelixis, Inc. (EXEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed oncology-focused biopharmaceutical company, Exelixis uses these filings to report material events, financial results, capital allocation decisions and changes in senior leadership.
Form 8-K filings for EXEL include items such as quarterly financial results and corporate updates, stock repurchase program authorizations and executive appointments or departures. For example, Exelixis has filed 8-Ks describing the authorization of a stock repurchase program for up to a specified amount of common stock before a stated date, as well as the appointment of an Executive Vice President, Research and Development and the planned transition of its General Counsel role. These filings complement the company’s earnings press releases by providing structured information on results of operations and significant corporate actions.
Investors and analysts can use Exelixis’ SEC filings to track how the company reports revenue from its cabozantinib franchise, outlines research and development and selling, general and administrative expenses, and communicates guidance ranges for future periods. While detailed financial statements and management discussion are found in periodic reports such as Forms 10-K and 10-Q, current reports on Form 8-K highlight timely developments that may affect the company’s outlook or governance.
On Stock Titan, EXEL filings are accompanied by AI-powered summaries designed to clarify the key points in complex documents. These summaries help readers quickly understand the implications of new filings, from capital return plans to leadership changes, while links to the full text allow for deeper review. The filings page also serves as a starting point for researching topics such as repurchase authorizations, executive transitions and other events that Exelixis has deemed material enough to disclose under SEC rules.
Exelixis insider equity award and holdings update. An Exelixis executive received 50,673 restricted stock units (RSUs) on 10/08/2025 under the 2017 Equity Incentive Plan. The RSUs vest in four equal installments, beginning 11/15/2026 and then each 11/15 thereafter until fully vested, meaning 25% vests on each vesting date. After the grant, the reporting person beneficially owns 713,161 shares in total, which includes 431,306 shares that will be issued upon vesting of other RSUs. The filing also reports 5,835 shares held in a 401(k) plan. The Form 4 was signed on 10/10/2025.
On August 29, 2025, Exelixis, Inc. announced an internal leadership change: Dana T. Aftab, Ph.D., currently the company’s Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, was appointed Executive Vice President, Research and Development. The filing states information about Dr. Aftab’s background, compensation arrangements, and any related-party transactions is incorporated by reference from the company’s definitive proxy statement on Schedule 14A filed April 16, 2025. Effective the same day, Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, and is entitled to payments under the company’s Change in Control and Severance Benefit Plan, as amended, and applicable law.